[Experimental toxicological and pharmacodynamic studies of a triple drug association (adrenaline, atropine and papaverine) with anti-bronchospastic activity].
The antibronchospastic value of the triple association adrenaline (1) + atropine (0,3) + papaverine (3) has been documented experimentally. Comparative investigations have been carried out with isoprenaline, metaproterenol, terbutaline and salbutamol. Toxicological and pharmacodynamic studies were done in the cardiovascular system and in vitro on certain muscles.
D000284:Administration, Oral; D000818:Animals; D001001:Anura; D001285:Atropine / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D001986:Bronchial Spasm / Q000188:drug therapy*; D002319:Cardiovascular System / Q000187:drug effects; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D004837:Epinephrine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects; D007082:Ileum / Q000187:drug effects; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008297:Male; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D010208:Papaverine / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D012119:Respiration / Q000187:drug effects; D014132:Trachea / Q000187:drug effects
D001285:Atropine; D010208:Papaverine; D004837:Epinephrine
Ricerche sperimentali tossicologiche e farmacodinamiche su una triplice associazione (adrenalina + atropina + papaverina) ad attività antibroncospastica.